We are live on ! Find out more
CNCE

Concert Pharmaceuticals, Inc.
CNCE

Delisted

CNCE was delisted on the 3rd of March, 2023.

Back to rankings

54 hedge funds and large institutions have $103M invested in Concert Pharmaceuticals, Inc. in 2014 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 14 increasing their positions, 13 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

31% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 13

25% more capital invested

Capital invested by funds: $82.6M → $103M (+$20.9M)

6% more funds holding

Funds holding: 51 → 54 (+3)

8% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 13

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
54
Holders Change
+3
Holders Change %
+5.88%
% of All Funds
1.44%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
17
Increased
14
Reduced
13
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SAM
Senzar Asset Management
New York
+$7.81M
2
ISL
Ingalls & Snyder LLC
New York
+$4.53M
3
QF
QVT Financial
New York
+$3.36M
4
Millennium Management
Millennium Management
New York
+$3.13M
5
BFA
BlackRock Fund Advisors
California
+$2.76M

Top Sellers

Rank Fund Capital Flow
1
EI
EAM Investors
California
-$3.82M
2
GTC
Ghost Tree Capital
New York
-$3.54M
3
RFC
Russell Frank Company
Washington
-$1.44M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.29M
5
TI
Turner Investments
Pennsylvania
-$1.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Investments
26
Two Sigma Investments
New York
$602K +$583K +45,163 New
BG
27
BlackRock Group
United Kingdom
$580K -$386K -29,887 -41%
BCM
28
Bridgeway Capital Management
Texas
$579K +$387K +30,000 +222%
Wells Fargo
29
Wells Fargo
California
$451K +$260K +20,173 +147%
Geode Capital Management
30
Geode Capital Management
Massachusetts
$411K +$60.6K +4,694 +18%
WMSA
31
Weiss Multi-Strategy Advisers
New York
$386K -$12.9K -1,000 -3%
CS
32
Credit Suisse
Switzerland
$329K +$187K +14,472 +142%
Goldman Sachs
33
Goldman Sachs
New York
$260K -$454K -35,120 -64%
SIM
34
SSI Investment Management
California
$249K +$241K +18,700 New
HCM
35
Highbridge Capital Management
New York
$238K +$231K +17,880 New
SKK
36
Shepherd Kaplan Krochuk
Massachusetts
$200K – – –
CSS
37
Cubist Systematic Strategies
Connecticut
$185K +$179K +13,866 New
Connor, Clark & Lunn Investment Management (CC&L)
38
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$180K +$174K +13,500 New
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
$175K +$170K +13,138 New
ProShare Advisors
40
ProShare Advisors
Maryland
$160K +$156K +12,044 New
Northern Trust
41
Northern Trust
Illinois
$158K – – –
BlackRock
42
BlackRock
New York
$145K -$163K -12,632 -54%
IAM
43
Iridian Asset Management
Connecticut
$145K -$44.3K -3,430 -24%
Bank of America
44
Bank of America
North Carolina
$92K +$89.6K +6,940 New
Citigroup
45
Citigroup
New York
$53K +$50.5K +3,907 +7,661%
Deutsche Bank
46
Deutsche Bank
Germany
$46K -$190K -14,720 -81%
BJ
47
BlackRock Japan
Japan
$46K +$12.2K +947 +38%
Morgan Stanley
48
Morgan Stanley
New York
$43K – – –
OIA
49
Optimum Investment Advisors
Illinois
$20K – – –
PCM
50
Prelude Capital Management
New York
$19K -$22K -1,700 -55%
1
2
3

CNCE Hedge Fund Activity: Q4 2014 in Review

54 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q4 2014, worth a combined $103M — up 25% from $82.6M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new CNCE positions and 13 closed out — a net gain of 4 holders — while 14 added to existing stakes and 13 trimmed.

The largest buyer was Senzar Asset Management, adding an estimated $7.81M. The largest seller was EAM Investors, exiting entirely with an estimated $3.82M sold.

  • 54 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q4 2014, up from 51 in Q3 2014.
  • Funds reported $103M of Concert Pharmaceuticals, Inc. stock for Q4 2014, up 25% quarter-over-quarter.
  • 17 funds opened new Concert Pharmaceuticals, Inc. positions in Q4 2014 and 13 closed out, a net change of +4 holders.
  • The largest Concert Pharmaceuticals, Inc. buyer in Q4 2014 was Senzar Asset Management, an estimated $7.81M added.
  • The largest Concert Pharmaceuticals, Inc. seller in Q4 2014 was EAM Investors, an estimated $3.82M sold.

Based on aggregated 13F filings for Q4 2014.